BUZZ-Vertex gains after FDA approves its non-opioid painkiller

** Shares of drugmaker Vertex Pharmaceuticals VRTX.O rise 8.23% to $474.50 premarket

** U.S. FDA approves co's oral drug Journavx as a treatment for moderate-to-severe acute pain

** Co has established a wholesale acquisition cost of $15.50 per 50 mg pill in the US

** The approval sets the stage for VRTX's next leg of growth - BMO Capital Markets

** Label looks fine, and the cost is reasonable though duration of therapy for acute pain in real world is to be decided for now - Jefferies

** Stock fell ~1% in 2024